Rhythm

Johnson and Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

Share by Ken Dropiewski on

More in Rhythm:

Share this story

IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment

See full post here as originally published on this site

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*